4DMedical Limited
FDMDF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -0.56 | -0.38 | -7.10 |
| FCF Yield | -46.47% | -15.48% | -10.21% | -8.31% |
| EV / EBITDA | -1.56 | -5.52 | -3.95 | -8.41 |
| Quality | ||||
| ROIC | -38.23% | -47.11% | -40.34% | -33.77% |
| Gross Margin | 92.07% | 92.24% | -3,378.55% | 26.62% |
| Cash Conversion Ratio | 1.15 | 0.86 | 0.72 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 101.21% | 42.48% | 49.06% | -5.07% |
| Free Cash Flow Growth | -10.88% | -28.45% | 14.40% | -90.59% |
| Safety | ||||
| Net Debt / EBITDA | 0.06 | 0.80 | 1.47 | 1.27 |
| Interest Coverage | 0.00 | -176.58 | -104.28 | -123.64 |
| Efficiency | ||||
| Inventory Turnover | 0.51 | 0.24 | 37.59 | 256.36 |
| Cash Conversion Cycle | -665.99 | -1,558.16 | 381.87 | -109.95 |